Thermo Fisher Scientific Inc. (NYSE:TMO) Shares Bought by Key Financial Inc

Key Financial Inc lifted its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 4.0% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 650 shares of the medical research company’s stock after acquiring an additional 25 shares during the quarter. Key Financial Inc’s holdings in Thermo Fisher Scientific were worth $345,000 as of its most recent SEC filing.

Several other hedge funds have also modified their holdings of TMO. Oakworth Capital Inc. boosted its holdings in shares of Thermo Fisher Scientific by 0.8% during the 4th quarter. Oakworth Capital Inc. now owns 2,767 shares of the medical research company’s stock worth $1,469,000 after purchasing an additional 23 shares during the last quarter. Migdal Insurance & Financial Holdings Ltd. grew its stake in shares of Thermo Fisher Scientific by 478.8% in the fourth quarter. Migdal Insurance & Financial Holdings Ltd. now owns 2,078 shares of the medical research company’s stock worth $1,107,000 after acquiring an additional 1,719 shares in the last quarter. Slow Capital Inc. grew its stake in shares of Thermo Fisher Scientific by 0.3% in the fourth quarter. Slow Capital Inc. now owns 7,715 shares of the medical research company’s stock worth $4,096,000 after acquiring an additional 21 shares in the last quarter. Sfmg LLC grew its stake in shares of Thermo Fisher Scientific by 1.2% during the fourth quarter. Sfmg LLC now owns 5,718 shares of the medical research company’s stock worth $3,035,000 after purchasing an additional 66 shares in the last quarter. Finally, TRUE Private Wealth Advisors boosted its stake in Thermo Fisher Scientific by 13.8% in the fourth quarter. TRUE Private Wealth Advisors now owns 1,368 shares of the medical research company’s stock valued at $726,000 after acquiring an additional 166 shares in the last quarter. 89.23% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other news, SVP Michael A. Boxer sold 14,566 shares of Thermo Fisher Scientific stock in a transaction dated Wednesday, February 7th. The shares were sold at an average price of $562.00, for a total value of $8,186,092.00. Following the completion of the transaction, the senior vice president now directly owns 12,901 shares of the company’s stock, valued at approximately $7,250,362. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 10,000 shares of the business’s stock in a transaction dated Tuesday, March 12th. The shares were sold at an average price of $597.98, for a total transaction of $5,979,800.00. Following the completion of the transaction, the chief executive officer now directly owns 123,816 shares of the company’s stock, valued at approximately $74,039,491.68. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP Michael A. Boxer sold 14,566 shares of the business’s stock in a transaction dated Wednesday, February 7th. The shares were sold at an average price of $562.00, for a total transaction of $8,186,092.00. Following the transaction, the senior vice president now directly owns 12,901 shares of the company’s stock, valued at $7,250,362. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 50,277 shares of company stock worth $28,513,384. 0.32% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

TMO has been the subject of several research analyst reports. HSBC upped their price objective on shares of Thermo Fisher Scientific from $630.00 to $660.00 and gave the company a “buy” rating in a research note on Wednesday. Citigroup initiated coverage on shares of Thermo Fisher Scientific in a research note on Monday, March 18th. They issued a “neutral” rating and a $620.00 price objective for the company. Sanford C. Bernstein restated a “market perform” rating on shares of Thermo Fisher Scientific in a research note on Monday, January 8th. Barclays cut shares of Thermo Fisher Scientific from an “overweight” rating to an “equal weight” rating and upped their target price for the company from $475.00 to $555.00 in a report on Wednesday, January 24th. Finally, The Goldman Sachs Group upped their target price on shares of Thermo Fisher Scientific from $550.00 to $640.00 and gave the company a “buy” rating in a report on Wednesday, April 10th. Five investment analysts have rated the stock with a hold rating and twelve have issued a buy rating to the stock. According to data from MarketBeat.com, Thermo Fisher Scientific currently has a consensus rating of “Moderate Buy” and a consensus price target of $604.69.

Thermo Fisher Scientific Price Performance

Shares of TMO stock traded down $7.30 during trading hours on Wednesday, hitting $547.25. The company’s stock had a trading volume of 1,609,039 shares, compared to its average volume of 1,540,198. The business has a fifty day moving average of $571.67 and a 200-day moving average of $526.87. The stock has a market cap of $208.89 billion, a price-to-earnings ratio of 35.44, a P/E/G ratio of 2.34 and a beta of 0.80. Thermo Fisher Scientific Inc. has a twelve month low of $415.60 and a twelve month high of $603.82. The company has a current ratio of 1.75, a quick ratio of 1.39 and a debt-to-equity ratio of 0.67.

Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings results on Wednesday, January 31st. The medical research company reported $5.67 EPS for the quarter, beating the consensus estimate of $5.64 by $0.03. Thermo Fisher Scientific had a net margin of 13.99% and a return on equity of 18.78%. The business had revenue of $10.89 billion for the quarter, compared to analyst estimates of $10.73 billion. During the same period in the prior year, the business earned $5.40 earnings per share. The company’s quarterly revenue was down 4.9% on a year-over-year basis. As a group, equities research analysts anticipate that Thermo Fisher Scientific Inc. will post 21.52 EPS for the current year.

Thermo Fisher Scientific Increases Dividend

The company also recently announced a quarterly dividend, which was paid on Monday, April 15th. Investors of record on Friday, March 15th were given a dividend of $0.39 per share. The ex-dividend date of this dividend was Thursday, March 14th. This represents a $1.56 dividend on an annualized basis and a yield of 0.29%. This is a positive change from Thermo Fisher Scientific’s previous quarterly dividend of $0.35. Thermo Fisher Scientific’s dividend payout ratio (DPR) is 10.10%.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.